The isolation, characterization, and development of a novel class of potent antimitotic macrocyclic depsipeptides: The cryptophycins

Anticancer Agents from Natural Products

Volumn , Issue , 2005, Pages 151-170

  Al Awar, Rima S ^a   Shih, Chuan ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGAE; ALKALOIDS; CLINICAL RESEARCH; RESEARCH LABORATORIES;

CLINICAL EVALUATION; COLLABORATIVE STRUCTURES; MITOTIC SPINDLE FUNCTION; MULTIDRUG RESISTANTS; PHARMACOLOGICAL PROPERTIES; PRECLINICAL STUDIES; UNIVERSITY OF HAWAII; WAYNE STATE UNIVERSITY;

TUMORS;

EID: 84906295977     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (85)

1. Schwartz, R. E. et al., Pharmaceuticals from cultured algae. J. Ind. Microbiol., 5, 118–126, 1990.
2. Patterson, G. M. et al., Antineoplastic activity of cultured blue-green-algae (Cyanophyta). J. Phycol., 27, 530–536, 1991
3. Corbett, T. H. et al., Cytoxic anticancer drugs: models and concepts for drug discovery and development; Valeriote, F. A., Corbett, T. H., Baker, L. H., Eds., Kluwer Academic Publishers, 35–87, 1992.
4. Valeriote, F. A. et al., Discovery and development of anticancer agents, Valeriote, F. A., Corbett, T. H., Baker, L. H., Eds., Kluwer Academic Publishers, 67–93, 1997.
5. Golakoti, T. et al., Total structures of cryptophycins, potent antitumor depsipeptides from the bluegreen alga Nostoc sp. Strain GSV 224. J. Am. Chem. Soc., 116, 4729–4737, 1994.
6. (b) Golakoti, T. et al., Structure determination, conformational analysis, chemical stability studies, and antitumor evaluation of the cryptophycins. Isolation of 18 new analogs from Nostoc sp. strain GSV 224, J. Am. Chem. Soc., 117, 12030–12049, 1995.
7. Corbett, T. H. et al., Anticancer Drug Development Guide. Teicher, B. A., Ed., Humana Press, 75–99, 1997.
8. (b) Corbett, T. H. et al., Discovery of cryptophycin-1 and BCN-183577: examples of strategies and problems in the detection of antitumor activity in mice. Invest. New Drugs, 15, 207–218, 1997.
9. Barrow, R. A. et al., Total synthesis of cryptophycins. Revision of the structures of cryptophycins A and C. J. Am. Chem. Soc., 117, 2479–2490, 1995.
10. Kerksiek, K. et al., Interaction of cryptophycin 1 with tubulin and microtubules. FEBS Lett., 377, 59–61, 1995.
11. Smith, C. D., Zhang, X. Mechanism of action of cryptophycin. Interaction with the Vinca alkaloid domain of tubulin. J. Biol. Chem., 271, 6192–6198, 1996.
12. Bai, R. et al., Characterization of the interaction of cryptophycin 1 with tubulin: binding in the Vinca domain, competitive inhibition of dolastatin 10 binding, and an unusual aggregation reaction. Cancer Res., 56, 4398–4406, 1996.
13. Mooberry, S. L., Taoko, C. R., Busquets, L. Cryptophycin 1 binds to tubulin at a site distinct from the colchicine binding site and at a site that may overlap the vinca binding site. Cancer Lett., 107, 53–57, 1996.
14. Panda, D. et al., Mechanism of action of the unusually potent microtubule inhibitor cryptophycin 1. Biochemistry, 36, 12948–12953, 1997.
15. Mooberry, S. L., Busquets, L., Tien, G. Induction of apoptosis by cryptophycin 1, a new antimicrotubule agent. Int. J. Cancer, 73, 440–448, 1997.
16. Smith, C. D. et al., Cryptophycin: a new antimicrotubule agent active against drug-resistant cells. Cancer Res, 54, 3779–3784, 1994.
17. (b) Wagner, M. M. et al., In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines. Cancer Chemother. Pharmacol., 43, 115–125, 1999.
18. Panda, D. et al., Antiproliferative mechanism of action of cryptophycin-52: kinetic stabilization of microtubule dynamics by high-affinity binding to microtubule ends. Proc. Nat. Acad. Sci. USA, 95, 9313–9318, 1998. 11.
19. Farrell, K. W., Jordan, M. A. A kinetic analysis of assembly-disassembly at opposite microtubule ends. J. Biol. Chem., 257, 3131–3138, 1982.
20. Farrell, K. W. et al., Phase dynamics at microtubule ends: the coexistence of microtubule length changes and treadmilling. J. Cell Biol., 104, 1035–1046, 1987.
21. Wilson, L., Jordan, M. A. Pharmacological probes of microtubule function. Modern Cell Biol., 13, 59–83, 1994.
22. Jordan, M. A., Wilson, L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr. Opin. Cell Biol., 10, 123–130, 1998.
23. Yvon, A-M. C., Wadsworth, P., Jordan, M. A. Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol. Biol. Cell, 10, 947–959, 1999.
24. Wilson, L., Panda, D., Jordan, M. A. Modulation of microtubule dynamics by drugs: a paradigm for the actions of cellular regulators. Cell Struct. Funct., 24, 329–335, 1999.
25. Jordan, M. A. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr. Med. Chem: Anti-cancer Agents, 2, 1–17, 2002.
26. Jordan, M. A., Wilson, L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer, 4, 253–265, 2004.
27. Fray A. H., Intramolecular aminolysis of trichloroethyl esters: a mild macrocyclization protocol for the preparation of cryptophycin derivatives. Tetrahedron Asymmetry, 9, 2777–2781, 1998.
28. Martinelli, M. J. et al., Dibutyltin oxide catalyzed selective sulfonylation of β-chelatable primary alcohols. Org. Lett., 1, 447–450, 1999.
29. Martinelli, M. J., Vaidyanathan, R., Khau, V. V., Selective monosulfonylation of internal 1,2-diols catalyzed by di-n-butyltin oxide. Tetrahedron Lett., 41, 3773–3776, 2000.
30. Varie, D. L. et al., Bioreduction of (R)-carvone and regioselective Baeyer-Villiger oxidations: application to the asymmetric synthesis of cryptophycin fragment A. Tet. Lett., 39, 8405–8408, 1998.
31. Dhokte, U. P. et al., A novel approach for total synthesis of cryptophycins via asymmetric crotylboration protocol. Tet. Lett., 39, 8771–8774, 1998.
32. Furuyama, M., Shimizu, I. A short enantioselective synthesis of a component of cryptophycin A and arenastatin A. Tetrahedron Asymmetry, 9, 1351–1357, 1998.
33. Liang, J. et al., Synthesis of unit A of cryptophycin via a [2,3]-Wittig rearrangement. J. Org. Chem., 64, 1459–1463, 1999.
34. Liang, J. et al., Synthesis of cryptophycin 52 using the Sharpless asymmetric dihydroxylation: diol to epoxide transformation optimized for a base-sensitive substrate. J. Org. Chem., 65, 3143–3147, 2000.
35. Pousset, C; Haddad, M., Larcheveque, M. Diastereocontrolled synthesis of unit A of cryptophycin. Tetrahedron, 57, 7163–7167, 2001.
36. Raghavan, S., Tony, K. A. Sulfinyl moiety as an internal nucleophile. 1. Efficient stereoselective synthesis of fragment A of cryptophycin 3. J. Org. Chem., 68, 5002–5005, 2003.
37. Phukan, P., Sasmal, S., Maier, M. E. Flexible routes to the 5-hydroxy acid fragment of the cryptophycins. Eur. J. Org. Chem., 9, 1733–1740, 2003.
38. Moore, R. E. et al., The search for new antitumor drugs from blue-green algae. Current Pharmaceutical Design, 2, 317–330, 1996.
39. Moore, R. E. Cyclic peptides and depsipeptides from cyanobacteria: a review. J. Ind. Microbiol., 16, 134–143, 1996.
40. Al-awar, R. S. et al., Preparation of novel cryptophycin pharmaceuticals. PCT Int. Appl., 293 pp. WO 9808505 A1 19980305, 1998.
41. Al-awar, R. S. et al., A convergent approach to cryptophycin 52 analogues: synthesis and biological evaluation of a novel series of fragment a epoxides and chlorohydrins. J. Med. Chem., 46, 2985–3007, 2003.
42. Patel, V. F. et al., Novel cryptophycin antitumor agents: synthesis and cytotoxicity of fragment “B” analogues. J. Med. Chem., 42, 2588–2603, 1999.
43. Kobayashi, M. et al., Arenastatin A, a potent cytotoxic depsipeptide from the okinawan marine sponge Dysidea arenaria. Tetrahedron Lett., 35, 7969–7972, 1994.
44. Kobayashi, M., et al., The absolute stereostructure of arenastatin A, a potent cytotoxic depsipeptide from the Okinawan marine sponge Dysidea arenaria. Chem. Pharm. Bull., 42, 2196–2198, 1994.
45. Varie, E. et al., Synthesis and biological evaluation of cryptophycin analogs with substitution at C-6 (fragment C region). Bioorg. Med. Chem. Lett., 9, 369–374, 1999.
46. Norman, B. H. et al., Total synthesis of cryptophycin analogs. Isosteric replacement of the C-D ester. J. Org. Chem., 63, 5288–5294, 1998.
47. Shih, C. et al., Synthesis and biological evaluation of novel cryptophycin analogs with modification in the β-alanine region. Bioorg. Med. Chem. Lett., 9, 69–74, 1999.
48. Worzalla, J. F. et al., LY355702 and LY355703, new cryptophycin analogues with antitumor activity against human tumor xenografts. Proc. Am. Assoc. Cancer Res., 38, 225, 1997, (Abs. 1516).
49. Polin, L. et al., Preclinical antitumor activity of cryptophycin-52/55 (C-52; C-55) against human tumors in SCID mice. Proc. Am. Assoc. Cancer Res., 38, 225, 1997, (Abs. 1514).
50. Polin, L. et al., Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice. Invest. New Drugs, 15, 99–108, 1997.
51. Sessa, C. et al., Phase I and pharmacological studies of the cryptophycin analogue LY355703 administered on a single intermittent or weekly schedule. Eur. J. Cancer, 38, 2388–2396, 2002.
52. Stevenson, J. P. et al., Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days. Clin. Cancer Res., 8, 2524–2529, 2002.
53. Salamonczyk, G. M. et al., Total synthesis of cryptophycins via a chemoenzymatic approach. J. Org. Chem., 61, 6893–6900, 1996.
54. de Muys, J-M. et al., Synthesis and in vitro cytotoxicity of cryptophycins and related analogs. Bioorg. Med. Chem. Lett., 6, 1111–1116, 1996.
55. Rej, R. et al., Total synthesis of cryptophycins and their 16-(3-phenylacryloyl) derivatives. J. Org. Chem., 61, 6289–6295, 1996.
56. Gardinier, K. M., Leahy, J. W. Enantiospecific total synthesis of the potent antitumor macrolides cryptophycins 1 and 8. J. Org. Chem., 62, 7098–7099, 1997.
57. Ali, S. M., Georg, G. I. Formal syntheses of cryptophycin A and arenastatin A. Tetrahedron Lett., 38, 1703–1706, 1997.
58. Georg, G. I., Ali, S. M., Stella, V. J. Halohydrin analogues of cryptophycin 1: synthesis and biological activity. Bioorg. Med. Chem. Lett., 8, 1959–1962, 1998.
59. Eggen, M., Georg, G. I. Enantioselective synthesis of a 3β-dephenylcryptophycin synthon. Bioorg. Med. Chem. Lett., 8, 3177–3180, 1998.
60. White, J. D., Hong, J., Robarge, L. A. Total synthesis of cryptophycins-1, -3, -4, -24 (arenastatin A), and -29, cytotoxic depsipeptides from cyanobacteria of the Nostocaceae. J. Org. Chem., 64, 6206–6216, 1999.
61. Chakraborty, T. K., Das, S. Diastereoselective opening of trisubstituted epoxy alcohols: application in the studies directed toward the synthesis of octenoic acid moiety of cryptophycins. J. Indian Chem. Soc., 76, 611–616, 1999.
62. Christopher, J. A. et al., A synthesis of cryptophycin 4 using a planar chiral molybdenum cationic complex. Synlett., 4, 463–466, 2000.
63. Ghosh, A. K., Bischoff, A. A convergent synthesis of (+)-cryptophycin B, a potent antitumor macrolide from Nostoc sp. Cyanobacteria. Org. Lett., 2, 1573–1575, 2000.
64. Barrow, R. A. et al., Synthesis of 1-aza-cryptophycin 1, an unstable cryptophycin. An unusual skeletal rearrangement. Tetrahedron, 56, 3339–3351, 2000.
65. Eggen, M. et al., Total synthesis of cryptophycin-24 (Arenastatin A) amenable to structural modifications in the C16 side chain. J. Org. Chem., 65, 7792–7799, 2000.
66. Eggen, MJ., Nair, S. K., Georg, G. I. Rapid entry into the cryptophycin core via an acyl-β-lactam macrolactonization: total synthesis of cryptophycin-24. Org. Lett., 3, 1813–1815, 2001.
67. Smith, A. B. et al., First generation design, synthesis, and evaluation of azepine-based cryptophycin analogues. Org. Lett., 3, 4063–4066, 2001.
68. Martinelli, M. J. et al., Reaction of cryptophycin 52 with thiols. Tetrahedron Lett., 43, 3365–3367, 2002.
69. Li, L-H., Tius, M. A. Stereospecific synthesis of cryptophycin 1. Org. Lett., 4, 1637–1640, 2002.
70. Hoard, D. W. et al., Synthesis of cryptophycin 52 using the Shi epoxidation. Org. Lett., 4, 1813–1815, 2002.
71. (s) Smith, A. B. et al., Design, synthesis, and evaluation of azepine-based cryptophycin mimetics. Tetrahedron, 59, 6991–7009, 2003.
72. Vidya, R. et al., Synthesis of cryptophycins via an N-acyl-β-lactam macrolactonization. J. Org. Chem., 68, 9687–9693, 2003.
73. Ghosh, A. K., Swanson, L. Enantioselective synthesis of (+)-cryptophycin 52 (LY355703), a potent antimitotic antitumor agent. J. Org. Chem., 68, 9823–9826, 2003.
74. Smith, C. D., Zhang, X. Mechanism of action of cryptophycin. Interaction with the Vinca alkaloid domain of tubulin. J. Biol. Chem., 271, 6192–6198, 1996.
75. Kessel, D., Luo, Y. Cells in cryptophycininduced cell-cycle arrest are susceptible to apoptosis. Cancer Lett., 151, 25–29, 2000.
76. Barbier, P. et al., In vitro effect of cryptophycin 52 on microtubule assembly and tubulin: molecular modeling of the mechanism of action of a new antimitotic drug. Biochemistry, 40, 13510–13519, 2001.
77. Watts, N. R. et al., The cryptophycin-tubulin ring structure indicates two points of curvature in the tubulin dimer. Biochemistry, 41, 12662–12669, 2002.
78. Drew, L et al., The novel antimicrotubule agent cryptophycin 52 (LY355703) induces apoptosis via multiple pathways in human prostate cancer cells. Clinical Cancer Res., 8, 3922–3932, 2002.
79. Shih, C., Teicher, B. A. Cryptophycins: a novel class of potent antimitotic antitumor depsipeptides. Curr. Pharm. Design, 7, 1259–1276, 2001.
80. Shih, C. et al., Synthesis and structure-activity relationship studies of cryptophycins: a novel class of potent antimitotic antitumor depsipeptides. ACS Symposium Series, 796 (Anticancer Agents), 171–189, 2001.
81. Eggen, MJ., Georg, G. I. The cryptophycins: their synthesis and anticancer activity. Med. Res. Rev., 22, 85–101, 2002
82. Tius, M. A. Synthesis of the cryptophycins. Tetrahedron, 58, 4343–4367, 2002.
83. Li, T., Shih, C. Structure activity relationships of cryptophycins, a novel class of antitumor antimitotic agents. Frontiers Biotech. Pharm., 3, 172–192, 2002.
84. Hong, J., Zhang, Li. Novel approaches to the synthesis of cryptophycin and related depsipeptides. Frontiers Biotech. Pharm., 3, 193–213, 2002.
85. Tius, M. A. Cryptophycin synthesis. Handbook Environ. Chem., 3 (Part P), 265–305, 2003.